Skip to content
Bamboo Works
Search
Register / Sign in
MSCI China | MSCI China Small-Cap | Hang Seng Index | Hang Seng China Enterprise
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Premium Content
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us
  • Eng
  • 简中
  • 繁中
Menu
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Premium Content
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us

Eli Lilly

Innogen Pharma

Innogen Pharma jostles for a slice of the weight-loss market

The developer of diabetes and anti-obesity drugs has applied for a Hong Kong IPO as it prepares for battle in a crowded arena Key Takeaways: Innogen is expected to launch…
December 13, 2024
派格生物減肥藥

PegBio aims to bulk up its finances to deliver weight-loss drugs

The Chinese developer of anti-obesity and diabetes drugs has applied for a Hong Kong listing to fund its commercial plans, but will face strong competition Key Takeaways: The company’s core…
November 21, 2024
The drug maker failed to generate any revenue in the first half of 2024 even with three major commercialized products in hand.

Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs

The drug maker failed to generate any revenue in the first half of 2024 even with three major commercialized products in hand Key Takeaways: Ascletis Pharma has shifted to weight…
September 27, 2024
1672.HK
This biopharmaceutical company reported a surge in half-year revenues but logged a bigger net loss, as investors look ahead to the launch of its new weight-loss drug.

Innovent Bio hopes for plus-sized profits from obesity drug

The biopharmaceutical company reported a surge in half-year revenues but logged a bigger net loss, as investors look ahead to the launch of its new weight-loss drug Key Takeaways: Sales…
September 5, 2024
1801.HK
The developer of treatments for cancer and bone fractures is branching out into the weight-loss market, but faces strong competition there.

Jiuyuan Gene seeks IPO cash for bet on weight-loss drugs

The developer of treatments for cancer and bone fractures is branching out into the weight-loss market, but faces strong competition there Key Takeaways: At present, Jiuyuan Gene relies heavily on…
August 16, 2024
The newly floated biotech can boast big-name backers and counts more than a dozen biopharma heavyweights among its customers, but it is still awash with red ink.

AI drugs researcher QuantumPharm makes market debut on long road to profit

The newly floated biotech can boast big-name backers and counts more than a dozen biopharma heavyweights among its customers, but it is still awash with red ink Key Takeaways: QuantumPharm’s…
June 13, 2024
2228.HK
ProfoundBio to be bougth by Genmab

ProfoundBio discovers the joys of having a wealthy owner

The company has become the latest in a recent string of China-related innovative drug makers to be purchased by larger foreign buyers Key Takeaways: Cancer treatment maker ProfoundBio announced it…
April 8, 2024
Load more

Recent Articles

Innogen Pharma
December 13, 2024

Innogen Pharma jostles for a slice of the weight-loss market

November 21, 2024

PegBio aims to bulk up its finances to deliver weight-loss drugs

September 27, 2024

Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs

1672.HK
September 5, 2024

Innovent Bio hopes for plus-sized profits from obesity drug

1801.HK
August 16, 2024

Jiuyuan Gene seeks IPO cash for bet on weight-loss drugs

June 13, 2024

AI drugs researcher QuantumPharm makes market debut on long road to profit

2228.HK
April 8, 2024

ProfoundBio discovers the joys of having a wealthy owner

RELATED ARTICLES

  1. 派格生物減肥藥
    November 21, 2024
    PegBio aims to bulk up its finances to deliver weight-loss drugs
  2. March 6, 2025
    Earnings blow for CSPC Pharma as the state drives a hard bargain
    1093.HK
  3. December 5, 2024
    Xuanzhu Biopharm set for spin-off in Hong Kong IPO
    0460.HK
  4. December 19, 2024
    Hengrui Pharma accelerates bid for global brand status
    600276.SHG
  5. January 9, 2025
    Cancer drug maker Genfleet joins Hong Kong IPO influx
  6. December 12, 2024
    Cloudbreak Pharma sets sights on Hong Kong IPO after license deal
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva

China stock insights and analysis for global investors: Bamboo Works unlocks investment opportunities in Chinese companies listed in the U.S. & Hong Kong.

  • About Us
  • Fast News
  • Premium Content
  • Expert Corner
  • China ESG
Facebook Twitter Linkedin Weixin Weibo Youtube

Categories

  • New Energy
  • IPO
  • Infrastructure/Resources
  • Education
  • Finance
  • Social Media/Entertainment
  • Consumer
  • Ecommerce
  • Healthcare/biotech
  • Property

Newsletter

Discover hidden China stock gems in our weekly newsletter
Copyright © 2024 Bamboo Works. All rights reserved.